After finding that non-clinical factors influence outcomes, researchers discuss closing gaps.
Recommending expanded screening could help African Americans, suggests new research.
Interim results suggest advantages over crizotinib for ALK-positive disease.
New findings point to the severest impacts by race and ethnicity, anatomic site.
Nationwide data show new risk factors and support preemptive testing.
Risk model aims to improve antibiotic stewardship in febrile patients.
1 / 5
TERAVOLT consortium finds high mortality and barriers to treatment.
Review compares strengths, limitations of available systems.
International registry begins to shed light on increased risk.